{"id":"NCT01258049","sponsor":"Proto Pharma Ltd","briefTitle":"Superiority of ArTiMist Versus Quinine in Children With Severe Malaria","officialTitle":"A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMistâ„¢ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-08","completion":"2012-09","firstPosted":"2010-12-10","resultsPosted":"2014-02-28","lastUpdate":"2014-02-28"},"enrollment":151,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plasmodium Falciparum Malaria"],"interventions":[{"type":"DRUG","name":"Artemether Sublingual Spray","otherNames":["ArTiMist"]},{"type":"DRUG","name":"Quinine","otherNames":[]}],"arms":[{"label":"ArTiMist","type":"EXPERIMENTAL"},{"label":"Quinine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by \\>= 90% within 24 hours after the start of treatment in children with severe malaria, or uncomplicated malaria with gastrointestinal complications","primaryOutcome":{"measure":"Parasitological Success (MITT)","timeFrame":"24 hours after start of treatment","effectByArm":[{"arm":"ArTiMist","deltaMin":66,"sd":null},{"arm":"Quinine","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.005"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Burkina Faso","Ghana","Rwanda"]},"refs":{"pmids":["26303805"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":77},"commonTop":["Malaria","Anaemia","Pyrexia","Respiratory Tract Infection","Cough"]}}